[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553868":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":27,"locations":38,"responsibleParty":57,"collaborators":18,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":18,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":18,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":18,"overallStatus":41,"whyStopped":18,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Helwan University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dapagliflozin group","ACTIVE_COMPARATOR","Dapagliflozin group who consist of at least 20 breast cancer patients who receive 4 cycles of anthracyclines ( each cycle every 21 days ) with dapagliflozin 10 mg tablet once daily.",[13],"Drug: Dapagliflozin 10mg Tab",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","Control group who consist of at least 20 breast cancer patients who receive 4 cycles of anthracyclines ( each cycle every 21 days ) only.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Dapagliflozin 10mg Tab","Dapagliflozin 10 mg tablet orally, once daily. Started 7 days before the first cycle of anthracyclines till the end of last anthracyclines dose.\n\ntaken orally, once daily. Started from 5 to 7 days before the first cycle of anthracyclines till the end of last anthracycline dose.",[9],[26],"Dapablix 10 mg",[28,34],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Shimaa Nabil Abd elaziz Hassanein, bachelor","CONTACT","+201115817090","01552556910","Shimaa.Nabil@pharm.helwan.edu.eg",{"name":35,"role":30,"phone":36,"phoneExt":18,"email":37},"Sara Mohamed Mohamed, Lecturer","+201016903404","Sara.abdel-motaleb@pharm.helwan.edu.eg",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Al demerdash hospital at oncology departement","RECRUITING","Cairo","Cairo Governorate","202","Egypt","EG",{"type":48,"coordinates":49},"Point",[50,51],31.24967,30.06263,{"lat":51,"lon":50},[54],{"name":55,"role":30,"phone":56,"phoneExt":18,"email":33},"Shimaa N abdelaziz, bachelor","01115817090",{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Sara Mohamed Mohamed Abdel Motaleb","Lecturer of Clinical Pharmacy - Pharmacy Practice Department, Faculty of Pharmacy - Helwan University","100553868","phase-4-cardiotoxicity-in-breast-cancer-patients-100553868",false,"NCT06491680","Cardiotoxicity in Breast Cancer Patients","Evaluation of the Cardioprotective Effect of Dapagliflozin on Anthracyclines-Induced Cardiotoxicity in Breast Cancer Patients","Inclusion Criteria:\n\n1. patients with pathologically proved invasive breast carcinoma.\n2. Patients were indicated for anthracyclines containing adjuvant chemotherapy or new adjuvant anthracyclines.\n3. Renal function (eGFR \\> 30 mL\u002Fminute per 1.73 m2 )\n4. LVEF is more than 50 %\n5. Age ≥ 18 and ≤ 60 years old\n\nExclusion Criteria:\n\n1. patients with any cardiac condition that contraindicate the use of anthracyclines, like heart failure, arrythmia, stroke and myocardial infarction.\n2. Previous anthracycline-containing regimens and any cardiotoxic chemotherapy regimens\n3. pregnant or breastfeeding patients\n4. patients receiving any other cardiotoxic agents.\n5. Patients with diabetic ketoacidosis or patients with type 1 diabetes mellitus.\n6. Mediastinal irradiation including heart.\n7. Refusal to sign the written informed consent.","ALL","18 Years","60 Years",{"count":72,"type":73},40,"ESTIMATED","INTERVENTIONAL",[76],"PHASE4","The goal of this clinical trial is to learn if dapagliflozin drug has a cardioprotective effect against anthracyclines-induced cardiotoxicity. It will also learn about the safety of dapagliflozin drug.\n\nAim of the study:\n\nEvaluate cardioprotective effect and safety of dapagliflozin against anthracyclines-induced cardiotoxicity.\n\nThe main questions it aims to answer are:\n\n1. Does the drug lower the cardiotoxicity which induced by anthracyclines?\n2. What medical problems do participants have when taking dapagliflozin drug?\n\nTreatment\n\n1. Anthracyclines by 4 cycles included doxorubicin 50-60 mg\u002Fm2 with cyclophosphamide 600 mg as a combination or epirubicin 90-100 mg\u002Fm2 with cyclophosphamide 600 mg as a combination.\n2. Dapagliflozin 10 mg tablet orally, once daily. Started 7 days before the first cycle of anthracyclines till the end of last anthracyclines dose.",[79],"Breast Cancer","2025-09-16",{"date":82,"type":83},"2025-09-22","ACTUAL",{"date":85,"type":83},"2024-09-10",{"date":87,"type":73},"2026-06",{"name":5,"class":6},1]